REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class
Debt / NOTE 1.750% 2/1
Market price (% of par)
92.3%
Total 13F principal
$253,368,000
Principal change
-$43,237,000
Total reported market value
$234,923,888
Number of holders
24
Value change
-$49,050,168
Number of buys
7
Number of sells
17

Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q4 2022

As of 31 Dec 2022, REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 was held by 24 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $253,368,000 in principal (par value) of the bond. The largest 10 bondholders included FRANKLIN RESOURCES INC, COWEN AND COMPANY, LLC, LAZARD ASSET MANAGEMENT LLC, AVIVA PLC, Antara Capital LP, Voya Investment Management LLC, Kohlberg Kravis Roberts & Co. L.P., SSI INVESTMENT MANAGEMENT LLC, DeepCurrents Investment Group LLC, and CAPSTONE INVESTMENT ADVISORS, LLC. This page lists 24 institutional bondholders reporting positions for the Q4 2022 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.